期刊文献+

miR-203影响K562细胞对三氧化二砷敏感性的研究 被引量:1

Effects of miR-203 K562 Cells to Arsenic Trioxide Sensitivity Study
下载PDF
导出
摘要 目的 探讨has-miR-203与慢性粒细胞白血病三氧化二砷(As2O3)治疗的敏感性的关系及可能的作用机制.方法 体外培养K562细胞,利用LipofectamineTM 2000将miR-203模拟物转染至K562细胞,流式细胞术检测转染效率,MTT法检测使用miR-203,As2O3以及两者联合使用对细胞增殖的抑制率,并计算IC50;最后用金正均Q值法评价用药效果.结果 miR-203转染至K562细胞,联合As2O3显著抑制K562细胞增殖,抑制效果较各单独使用组作用明显增强.As2O3浓度为0.05,0.1,0.2和0.4 μmol/L时的抑制率分别为24.0%±5.0%,33.1%±1.5%,39.4%±3.4%和47.1%±5.5%.micRNA-203浓度为5,10,20和40 μmol/L时的抑制率分别为27.0%±6.7%,38.8%±3.2%,44.6%±3.0%和59.6%±3.7%.不同浓度梯度的As2O3联合20 μmol/L的micRNA-203抑制率分别为46.9%±3.2%,48.9%±3.9%,50.2%±5.5%和56.1%±1.9%.结论 当一定浓度的miR-203与不同浓度梯度的As2O3联合之后,对K562细胞的增殖抑制表现为相加作用,提高了K562细胞对As2O3的敏感性,为白血病的治疗提供新的依据. Objective To study the effect of hsa-miR-203 for enhancing the arsenic trioxide sensitivity of leukemic K562 cells and its possible acting mechanism. Methods Cultured K562 cells in vitro,and hsa-miR-203 minies was transfected to K562 cells using LipofectamineTM 2000. The transfeeted rates were determined by flow cytometry. The inhibitory effects of ATO and miR-203 ,used singly or in combining on cell proliferation were detected by MTT. Their inhibition rate and IC^0 were cal- culated. Evaluate the drug effects with jinzhengjun Q valus. Results The growth inhibition rates was obivously enhanced when arsenic trioxidecombining with miR-203. Arsenic trioxide using singly, the inhibition rate were 24.0 %± 5.0 %, 33.1% ±1.5% ,39. 4%±3.4% and 47.1% ±5.5% ,respectively. MiR-203 using singly,the inhibition rate were 27.0% -t-6. 7%, 38. 8%±3.2% ,44. 6%±3. 0% and 59. 6%±3.7% ,respectively. The inhibition rate were 46.9%±3.2% ,48. 9% ±3.9%, 50. 2 % ± 5.5 % and 56.1%±1.9 %, respectively. When the same concentrations of miR-203 combined with arsenic trioxide. Conclusion Combined use of miR-203 and arsenic trioxide,could increase the sensitivity of K562 cells to As2O3 ,which provides a novel potential approach for treatment of leukemia.
出处 《现代检验医学杂志》 CAS 2013年第3期106-109,共4页 Journal of Modern Laboratory Medicine
基金 广东省科技厅社会发展项目(20118080702011).
关键词 AS2O3 hsa-miR-203 人慢性粒细胞白血病K562细胞 敏感性 As2O3 hsa-miR-203 human chronic myeloid leukemia K562 cells sensitivity
  • 相关文献

参考文献10

  • 1Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regu?lation[J]. Oncogene, 2006 ,25(46),6163-6169.
  • 2Vasudevan S, Tong YvSteitzJ A. Switching from re?pression to activation, microRNAs can up-regulate translation[J]. Science, 2007 ,318(5858),1931-1934.
  • 3Berezikov E, Guryev V, van de BeltJ .et al. Phyloge?netic shadowing and computational identification of human microRNA genes[J]. Cell,2005, 1200),21- 24.
  • 4Bueno MJ, Perez de Castro I, GOmez de Cedr6n M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABLI and BCR-ABLI oncogene expression[n. Cancer Cell,2008,13 (6) ,496-506.
  • 5刘金花,王晓丹,赵雪飞,唐庆华,展昭民,马军,李德山,邱林.三氧化二砷抑制耐药bcr-abl突变细胞株生长的机制[J].白血病.淋巴瘤,2010,19(7):421-424. 被引量:4
  • 6金正均.合并用药中的相加[J].中国药理学报,1980,1:70-73.
  • 7刘静,王小中.慢性粒细胞白血病相关microRNA的研究进展[J].分子诊断与治疗杂志,2010,2(4):280-283. 被引量:3
  • 8KrutzfeldtJ , Rajewsky N , Braich Rvet al. Silencing of microRNAs in vivo with' antagomirs'[J]. Nature, 2005,438(7068),685-689.
  • 9Greither T , Grochola LF, Udelnow Avet al."Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival"[J]. IntJ Cancer,2010, 126(1),73-80.
  • 10Blower PE,ChungJH, Verducci rs,? al. MicroR?NAs modulate the chemosensitivity of tumor cells[J]. Mol Cancer Ther,2008, 7(1),1-9.

二级参考文献37

  • 1Apperley JF.Part I.Mechanisms of resistance to imatinib in chronic myeloid leukaemia.Lancet Oncol,2007,8:1018-1029.
  • 2Bradeen HA,Eide CA,O'Hare T,et al.Comparison of imatinib mesylate,dasatinib (BMS-354825),and nilotinib (AMN107) in an Nethyl-N-nitnwourea (ENU)-based mutagenesis screen:high efficacy of drug combinations.Blood,2006,108:2332-2338.
  • 3Thomas X,Pigneux A,Raffoux E,et al.Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.Haematologica,2006,91:996-997.
  • 4Aribi A,Kantarjian HM,Estey EH,et al.Combination therapy with arsenic trioxide,all-trans retinoic acid,and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.Cancer,2007,109:1355-1359.
  • 5Jiong H,Yuan FL,Chuan FW,et al.Efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.PNAS,2009,106:3342-3347.
  • 6Percherancier Y,Germain-Desprez D,Galisson F,et al.Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation:sumoylation of PML and phnspho-switch control of its SUMO binding domain dissected in living cells.J Biol Chem,2009,284:16595-16608.
  • 7Weisshaar SR,Keusekotten K,Krause A,et al.Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML FEBS Lett,2008,582:3174-3178.
  • 8Tatham MH,Geoffroy MC,Shen L,et al.RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.Nat Cell Biol,2008,10:538-546.
  • 9Rollig C,Illmer T.The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma:a systematic review.Cancer Treat Rev,2009,35:425-430.
  • 10Vey N,Bosly A,Guerci A,et al.Arsenic trioxide in patients with myelodysplastic syndromes:a phase Ⅱ multicenter study.J Clin Oncol,2006,24:2465-2471.

共引文献122

同被引文献16

  • 1张旭辉,张日,朱子玲,王玮.三氧化二砷诱导K562细胞凋亡的机制探讨[J].中国实验血液学杂志,2004,12(5):558-562. 被引量:6
  • 2Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvi- ronment as a sanctuary for minimal residual disease in CML [ J ]. Biochem Pharmacol, 2010,80 (5) :602-612.
  • 3Wang GB, Chen XQ, Geng QR, et al. Arsenic trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of bl-integrin in K562 chronic myelogenous leukemia cell line[ J]. Leukemia Lymphoma, 2010,51 (6) :1090-1097.
  • 4Liu J, Wang XZ. Research advances on chronic mye-loid leukemia-re- lated microRNA[J]. J Mol Diagn Ther, 2010,2(4) :280-283.
  • 5Goussetis DJ, Gounaris E, Wu EJ, et al. Autophagie degradation of the BCR-ABL oncoprotein and generation of antileukemic response by arsenic trioxide[J]. Blood, 2012,120(17) :3555-3562.
  • 6Takai A, Toyoshima T, Uemura M, et al. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mu- tations[J]. Oncogene, 2009,28(4) :469-478.
  • 7Liu Z, Wu X, Duan Y, et al. AID expression is correlated with BCR-ABL expression in CML-LBC and can be down-regulated by As20s and/or imatinib [ J ]. Leukemia Research, 2011,35 ( 10 ) : 1355-1359.
  • 8Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155,203,210 and 222 in pancreatic tumors is associated with poorer survival[ J ]. Int J Cancer, 2010,126( 1 ) :73-80.
  • 9Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of micro RNA in vivo with antagomirs [.11- Nature, 2(105,438(7068) :685a589.
  • 10Porosnicu M, Nitmnaapalli R, Nguyen D, et al. Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against bcr-abl- positive acute leukemia cells[J]. Leukemia, 2001,15(5) :772-778.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部